Excess visceral fat in HIV lipodystrophy
2Approved adult indication; not general weight-loss treatment.
What does it do?
A GHRH analogue approved for excess abdominal fat in adults with HIV lipodystrophy; it is not approved for general weight loss.
Approved & studied uses
Community uses Reported, unvalidated
Approved / fat
20HIV-associated visceral fat reduction; durability depends on continued treatment.
Metabolic
20Triglycerides, lipids and fatty-liver research.
Muscle
20Lean-mass/density and IGF-1-related findings, not bodybuilding approval.
Reasons people report using it; these do not establish benefit.20
Evidence limits
View research →Benefits outside the studied HIV population cannot be assumed.1
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Cancer and pregnancy
Contraindicated with active malignancy or pregnancy.2
FDA-approved Egrifta formulations for excess abdominal fat in adults with HIV-associated lipodystrophy; not an approved general weight-loss treatment.
Molecular information
Amino-acid sequence
- His
- Ala
- Asp
- Gly
- Ile
- Phe
- Thr
- Asn
- Ser
- Tyr
- Arg
- Lys
- Val
- Leu
- Gly
- Gln
- Leu
- Ser
- Ala
- Arg
- Lys
- Leu
- Leu
- Gln
- Asp
- Ile
- Met
- Ser
- Arg
- Gln
- Gln
- Gly
- Glu
- Ser
- Asn
- Gln
- Glu
- Arg
- Gly
- Ala
- Arg
- Ala
- Arg
- Leu
44 residues · N → C20
Length44 amino acids
Molecular weight · Da5135.9 Da (free-base equivalent)
Formula, sequence notation & identity
Molecular formulaC221H366N72O67S2
His-Ala-Asp-Gly-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-LeuIdentity reported by Pep-Pedia; exact-product sequence and modifications have not been independently confirmed.
N-hexenoyl GHRF analogue.
Egrifta contains an acetate salt; formula shown excludes acetate.
Pep-Pedia identity details
44 amino acids · 5,135.9 Da
His-Ala-Asp-Gly-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-LeuReference description; checked chemical identity above takes precedence when available.20
Pharmacokinetics
How long does it stay in the body?
Human data
Reported half-life11 minutes2
Route / formulationSubcutaneous Egrifta WR 1.28 mg
50%of reference level
Illustrative model using reported human data.
About 3% remaining after 55 min
Five half-lives in this simplified model. This is not a prediction of when effects stop.
Evidence and model details
Single-dose mean; formulation-specific. Peak time of 0.15 hours is a separate measure.
Population: Healthy participants
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Unverified reference estimateNot independently confirmed
Reference half-life26 min19
Route / formulationSource page: Injectable. Exact PK route not verified.
The checked Egrifta WR formulation gives 11 minutes. Other tesamorelin formulations and source values are not interchangeable.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 2.17 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: FDA Egrifta Label
Source’s reported peak time: 9 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Visceral fat reduction
Pooled studies reported a −15.4% relative treatment effect at 26 weeks. This is visceral-fat change, not total-body weight loss.1
Reported timelines
Reference & communitySource expectations
IGF-1 weeks 1–2; metabolic changes 4–6; visceral-fat changes 8–12; trial outcomes 12–26. Wellness timelines unverified.20
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Duration of use
The source hides 11 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 7 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 24 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 21 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 27 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 16 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “3660 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Stack claims are not established safe combinations. Formulations require their own label instructions.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous | 1.28 mg, Egrifta WR | Once daily | HIV-associated abdominal fatProduct label | Not specified | 2 |
Population Adults with HIV lipodystrophy Context WR and SV are not substitutable. | |||||
| SubQSubcutaneous | 2 mg, original formulation | Once daily | Visceral adipose tissue reductionHuman study | 26 weeks | 1 |
Population 806 participants with HIV-associated abdominal fat Context Pooled phase 3 trials; original formulation differs from current WR. | |||||
| SubQSubQ (abdomen) | 1.4 mg daily | Once daily | HIV Lipodystrophy (FDA Approved)Reference report | Continuous treatment (effects reverse upon discontinuation) | 20 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Stack claims are not established safe combinations. Formulations require their own label instructions. Source tabs Injectable | |||||
| SubQSubQ (rotate sites) | 2 mg daily | Once daily | Visceral Fat ReductionReference report | Continuous treatment (effects reverse upon discontinuation) | 20 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Stack claims are not established safe combinations. Formulations require their own label instructions. Source tabs Injectable | |||||
| SubQSubQ (evening) | 1-2 mg daily | 5-7 days/week | Anti-aging/Body CompositionReference report | Continuous treatment (effects reverse upon discontinuation) | 20 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Stack claims are not established safe combinations. Formulations require their own label instructions. Source tabs Injectable | |||||
| SubQSubQ for 12 months | 2 mg daily | Once daily | NAFLD TreatmentReference report | Continuous treatment (effects reverse upon discontinuation) | 20 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Stack claims are not established safe combinations. Formulations require their own label instructions. Source tabs Injectable | |||||
| SubQSubQ for 20 weeks | 1 mg daily | Once daily | Cognitive Enhancement (Research)Reference report | Continuous treatment (effects reverse upon discontinuation) | 20 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Stack claims are not established safe combinations. Formulations require their own label instructions. Source tabs Injectable | |||||
| SubQSubQ with cycle breaks | 1-2 mg daily | Daily | Research ProtocolReference report | Continuous treatment (effects reverse upon discontinuation) | 20 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Stack claims are not established safe combinations. Formulations require their own label instructions. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- Continuous treatment (effects reverse upon discontinuation)
- Break
- No breaks required for FDA-approved use; off-label may cycle 3 months on/1 month off
Reported timing
Evening injection preferred for natural GH rhythm support
Side effects & safety
Cancer and pregnancy
Contraindicated with active malignancy or pregnancy.
2IGF-1 and glucose
IGF-1 elevation and glucose intolerance require monitoring.
2Common reactions
Fluid retention, joint discomfort, allergy and injection-site reactions.
2Risks
Glucose intolerance/diabetes, elevated IGF-1, edema, joint and injection reactions.
Exclusions
Active malignancy, disrupted hypothalamic-pituitary axis and pregnancy.
Stop symptoms
Severe allergy, suspicious growths, deteriorating glucose control or acromegaly-like symptoms.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
11 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Ipamorelin
Caution reportedGH-axis overlap.20
Reference report · Pep-Pedia label: Monitor CombinationCJC-1295
Caution reportedGHRH overlap.20
Reference report · Pep-Pedia label: Use CautionCJC-1295 with DAC
Avoidance reportedUnstudied GHRH duplication.20
Reference report · Pep-Pedia label: Use CautionInsulin
Caution reportedGlucose effects.20
Reference report · Pep-Pedia label: Monitor CombinationPrednisone
Caution reportedGlucocorticoid requirements may change.20
Reference report · Pep-Pedia label: Use CautionOctreotide
Avoidance reportedGH-release inhibition.20
Reference report · Pep-Pedia label: Avoid CombinationGrowth hormone
Avoidance reportedExcess GH-axis exposure.20
Reference report · Pep-Pedia label: Avoid CombinationCYP450-metabolized medicines
Label warningMonitor for altered clearance.2
Research contextGlucocorticoid replacement
Label warningReplacement requirements may change.2
Research contextSermorelin
Unverified pairingGHRH overlap.20
Reference report · Evidence context: Dose dependentMetformin
Unverified pairingNot proven to remove diabetes risk.20
Reference report · Pep-Pedia label: CompatibleNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
Egrifta WR 11.6-mg vial: only its supplied diluent.2
WR preparation
Label specifies 1.3 mL bacteriostatic water, yielding 8 mg/mL; 1.28 mg is 0.16 mL. Use the labeled 8 mg/mL concentration; dividing the nominal vial mass by added volume does not reproduce this product’s labeled concentration.2
WR storage
After mixing: 20–25°C; discard after 7 days. Do not freeze.2
No generalization
WR instructions do not apply to SV or research powders; use labeled final concentration.2
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia distinguishes Egrifta SV and WR; their volumes and storage are not interchangeable.
- Solvents mentioned
- Sterile water — SV / Bacteriostatic water — WR
- Reported parameters
- SV: source reports 0.5 mL sterile water for a 2 mg vial, then immediate use and disposal of remainder. · WR: source reports 1.3 mL BAC water for an 11.6 mg vial, then 20–25°C for up to 7 days without refrigeration. · The source’s general powder-refrigeration statement must be checked against the exact product label.
The source describes gentle mixing and avoiding vigorous shaking.
Use the checked label-specific preparation in the main profile. Retail research powders are not Egrifta SV or WR.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceFDA-approved formulationsReported appearanceWhite crystalline powderReported appearanceClear reconstituted solutionReported appearanceProper packaging integrityReported concernDiscolored or cloudy solutionReported concernVisible particles or precipitateReported variationCompounded formulations
20Vial sizes
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Checked product labels
These limits apply only to the named product and its specified diluent.
Egrifta WR
2After mixing with its supplied diluent, keep at room temperature. These instructions do not apply to research vials.
Egrifta SV
21Discard the unused mixed solution. SV and WR storage instructions are different.
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.20
Full storage notes from Pep-Pedia
20Unreconstituted powder: refrigerate at 2-8°C. Reconstituted solution: room temperature (20-25°C) — do NOT refrigerate after mixing. Use SV immediately, WR stable 7 days.
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements Scales, capacity & references
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Research findings
Human trialsSource context
Stack claims are not established safe combinations. Formulations require their own label instructions.
Compound identity & other names
A growth-hormone-releasing hormone analogue with an approved role in excess abdominal fat in adults with HIV-associated lipodystrophy. Its approved formulations have different dosing and preparation requirements.
Other names: Tesa · Egrifta · Egrifta SV · Egrifta WR · TH9507
FDA-approved Egrifta formulations for excess abdominal fat in adults with HIV-associated lipodystrophy; not an approved general weight-loss treatment.
How it may work
Stimulates pituitary GH and downstream IGF-1, affecting visceral adipose tissue.20
Reduced visceral fat in HIV-associated lipodystrophy
A pooled analysis of two phase 3 trials in 806 treated adults with HIV found a 15.4% treatment effect on visceral adipose tissue at 26 weeks.
1Product formulations
The Egrifta WR label uses 1.28 mg daily and an 11.6 mg vial. It explicitly says WR and SV are not substitutable; the original 2 mg research regimen is not a universal product instruction.
2Newer cognitive study found no clear benefit
The 2025 trial in people with HIV and abdominal obesity did not establish a neurocognitive benefit over standard care. It was underpowered and lacked a placebo arm.
3Research areas and evidence gaps
Excess visceral fat in HIV lipodystrophy. Approved adult indication; not general weight-loss treatment.2
- Benefits outside the studied HIV population cannot be assumed.
- Long-term cardiovascular safety is not established in the product label.
Community reports Unvalidated
Pep-Pedia discusses body composition and anti-aging beyond the approved indication. Its protocols should not override formulation-specific prescribing information.4
A secondary protocol description, not a clinical recommendation or a representative survey. Dose, product identity, other compounds and outcome reporting are not independently verified.
Search coverage and review status
The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.
- Checked
- 2026-10-12
- Search
- tesamorelin 2025 2026 clinical trial site:pubmed.ncbi.nlm.nih.gov
- Catalog
- Pep-Pedia ↗ · 13 listed references retained
- Targeted search, not an exhaustive systematic review.
- Bibliography-only entries are retained for traceability and are not treated as verified findings.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Pooled phase 3 trials of tesamorelin in HIVReview status not recorded
AI-PREPARED SUMMARY
In 806 adults with HIV and excess abdominal fat, the 26-week visceral-fat treatment effect was −15.4% versus placebo.
Reduced visceral fat in HIV-associated lipodystrophy
A pooled analysis of two phase 3 trials in 806 treated adults with HIV found a 15.4% treatment effect on visceral adipose tissue at 26 weeks.
2Egrifta WR prescribing informationReview status not recorded
AI-PREPARED SUMMARY
Defines the HIV-associated indication, contraindications and WR formulation. The label states WR and SV are not substitutable.
Product formulations
The Egrifta WR label uses 1.28 mg daily and an 11.6 mg vial. It explicitly says WR and SV are not substitutable; the original 2 mg research regimen is not a universal product instruction.
3Effects of tesamorelin on neurocognitive impairment in persons with HIVAbstract checked
AI-PREPARED SUMMARY
2025 six-month randomized open-label study found no clear cognitive benefit; limited power and no placebo arm constrain interpretation.
Newer cognitive study found no clear benefit
The 2025 trial in people with HIV and abdominal obesity did not establish a neurocognitive benefit over standard care. It was underpowered and lacked a placebo arm.
Additional research · Checked 2026-10-12
4Pep-Pedia: tesamorelin — community referenceCommunity source checked
AI-PREPARED SUMMARY
Accessed October 12, 2026. Reports commonly discussed protocols; these schedules are unvalidated descriptions, not evidence of safety or efficacy.
5Research catalog: labeled vial examplesCatalog checked
AI-PREPARED SUMMARY
Catalog shows 5, 10 and 20 mg research labels, distinct from Egrifta formulations. These are seller label examples, not verified contents, market-frequency estimates or supplier endorsements.
6Cardiovascular Risk Assessment (2025)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A modeled ten-year ASCVD risk change of 0.40 percentage points is described; it is not a demonstrated reduction in cardiovascular events.
Reported population / model
Humans
Reported study details
2 mg daily · 26 weeks · 0.40% reduction in 10-year ASCVD risk
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Anti-inflammatory Effects Study (2021)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Inflammatory mediator expression reportedly changed over a year; these biomarkers do not establish broader disease-prevention benefits.
Reported population / model
Humans
Reported study details
2 mg daily · 12 months · Reduced pro-inflammatory mediators
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8NAFLD Treatment Trial (2019)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The HIV/NAFLD study reportedly reduced liver fat by 37% and had favorable fibrosis findings; this is a specific treated population.
Reported population / model
Humans
Reported study details
2 mg daily · 12 months · 37% liver fat reduction
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Cognitive Enhancement Study (2012)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A trial in older adults reportedly improved selected executive/verbal-memory measures; it does not establish routine cognitive-enhancement use.
Reported population / model
Humans
Reported study details
1 mg daily · 20 weeks · Improved executive function and verbal memory
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10CTR-1011 Extended Safety Study (2011)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports sustained visceral-fat responses through 52 weeks, with 69% versus 33% meeting an 8% reduction threshold.
Reported population / model
Humans
Reported study details
2 mg daily · 26-52 weeks · 69% achieved ≥8% VAT reduction
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11LIPO-010 FDA Approval Trial (2010)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The HIV lipodystrophy trial reduced visceral fat by roughly 15%, with area changes of −24 versus +2 cm² on placebo.
Reported population / model
Humans
Reported study details
2 mg subcutaneous daily · 26 weeks · 15.4% VAT reduction vs placebo
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Metabolic effects of a growth hormone-releasing factor in patients with HIVLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
13Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reductionLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
14The effects of tesamorelin on muscle and bone parameters in HIV-infected patients with abdominal fat accumulationLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
15Effects of growth hormone-releasing factor on visceral fat, metabolic, and cardiovascular indices in human immunodeficiency virus-infected patients with abdominal fat accumulationLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
16Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension dataLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
17FDA Approval Package for Egrifta (tesamorelin) for injectionLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
18Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy agingLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
19Pep-Pedia: Tesamorelin — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 26 min and a peak time of 9 min. Stated attribution: FDA Egrifta Label. The checked Egrifta WR formulation gives 11 minutes. Other tesamorelin formulations and source values are not interchangeable. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
20Pep-Pedia: Tesamorelin — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
21Egrifta SV label: immediate use after mixingPrimary source checked
AI-PREPARED SUMMARY
Egrifta SV is used immediately after mixing; unused solution is discarded. Its instructions prohibit storing, freezing or refrigerating the mixed solution.